ICH Q11 Q&A - A Supporting Document for the Selection and Justification of Starting Materials

FDA discusses key concepts and clarification for starting materials selection based on ICH Q11 Q&A. Presenter: Anita Tiwari, Division of Lifecycle API Learn more at: https://www.fda.gov/drugs/news-events... --------------------  FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.     Upcoming Training - https://www.fda.gov/cdersbia SBIA Listserv - https://public.govdelivery.com/accoun... SBIA 2021 Playlist -    • 2021 CDER Small Business and Industry Assi...   SBIA LinkedIn:   / cder-small-business-and-industry-assistance   SBIA Training Resources - https://www.fda.gov/cdersbialearn Twitter -   / fda_drug_info   Email - [email protected]   Phone - (301) 796-6707 I (866) 405-5367

Process Validation and ICH Q7
▶︎

Process Validation and ICH Q7

Pharmacovigilance in Practice   From Safety Signals to Regulatory Action 1080
▶︎

Pharmacovigilance in Practice From Safety Signals to Regulatory Action 1080

Drug Substance Facilities – Hidden and Critical Intermediate
▶︎

Drug Substance Facilities – Hidden and Critical Intermediate

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
▶︎

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims
▶︎

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims

April 30, 2026 Meeting of the Oncologic Drugs Advisory Committee (ODAC)
▶︎

April 30, 2026 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing
▶︎

Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing

CDER & CBER All Hands: Implementing the FDA's Plausible Mechanism Framework
▶︎

CDER & CBER All Hands: Implementing the FDA's Plausible Mechanism Framework

Drug Master File (DMF) Submissions on New FDA Form 3938
▶︎

Drug Master File (DMF) Submissions on New FDA Form 3938

VRBPAC -- May 28 Meeting
▶︎

VRBPAC -- May 28 Meeting

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018
▶︎

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
▶︎

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Evaluation of Metal Impurities in Drug Substances
▶︎

Evaluation of Metal Impurities in Drug Substances

FDA Direct - Special Edition of FDA Direct
▶︎

FDA Direct - Special Edition of FDA Direct

FDA Direct: The Power of Real-Time Clinical Trials
▶︎

FDA Direct: The Power of Real-Time Clinical Trials

OTC Monograph Reform: OTC Sunscreen Drugs
▶︎

OTC Monograph Reform: OTC Sunscreen Drugs

ClinicalTrials.gov: Essentials for Academic Medical Centers – Pre-recorded Training Video
▶︎

ClinicalTrials.gov: Essentials for Academic Medical Centers – Pre-recorded Training Video

ICH Q12 Guidance and Emerging Technology Program (11of16) Generic Drugs Forum 2020
▶︎

ICH Q12 Guidance and Emerging Technology Program (11of16) Generic Drugs Forum 2020

Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018
▶︎

Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018

CBER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
▶︎

CBER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products